Protocols Used in Chemotherapy Treatment of Neonates and Infants
The protocols cited here are provided for quick reference, being necessary a full study of each complete protocol before prescribing; the protocols cited here are referenced in the final section of this book. Protocols may vary according to each institution. It is important to know every drug used in the protocol, to take the necessary care, and to perform the necessary examinations to avoid collateral effects and toxicity. The protocols for neonates and infants should be prescribed by an experienced oncopediatric physician—or under his/her constant supervision if they are prescribed by an oncopediatric physician who is not so accustomed to treating neonates and infants—and should be analyzed and handled by a pharmacist with extensive experience in the oncopediatric area. The protocols should also be administered by a nurse who is experienced in the areas of neonatology and oncology. It is essential that the protocols are devised by the institution before they need to be used, so the professionals have time to study and standardize drug brands, procedures for care, and other needs.
- 30.Pieters R, Schrappe M, Valsecchi MG, Biondi A, et al. INTERFANT-06: International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukemia. Stichting Kinderoncologie Nederland. 2016. https://www.skion.nl/workspace/uploads/Interfant-06_version16b_1aug2016_stop-Rand_MEC.pdf. Accessed 13 Jan 2017.
- 31.Interfant 2006. Stichting Kinderoncologie Nederland. https://www.skion.nl/voor-professionals/behandelrichtlijnen/protocollen/121/interfant-2006. Accessed 13 Jan 2017.
- 36.Busato M, Ceresér KMM, Onsten TGH, Feijó CS, Schostack N. Protocolo mais utilizado no tratamento da leucemia linfocítica aguda na infância em hospitais de Porto Alegre. Ped Mod. 2003;39:432–45.Google Scholar
- 38.Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children’s Cancer Group. Pediatric Cancer. http://ascopubs.org/doi/full/10.1200/jco.2005.09.095. Accessed 13 Jul 2017.
- 68.Veal GJ, Errington J, Sastry J, et al. Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens. Cancer Chemother Pharmacol. 2016;77:685–92. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819938. CrossRefGoogle Scholar